Valuation: PTC Therapeutics, Inc.

Market Cap 5.93B 5.08B 4.75B 4.35B 8.2B 568B 8.29B 56.26B 21.88B 285B 22.27B 21.79B 943B P/E 2026 *
46.5x
P/E 2027 * 26.3x
Enterprise Value 4.06B 3.48B 3.25B 2.98B 5.62B 389B 5.67B 38.51B 14.98B 195B 15.24B 14.91B 646B EV / Sales 2026 *
3.23x
EV / Sales 2027 * 2.76x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: PTC Therapeutics, Inc.

1 day+1.77%
1 week-0.19%
Current month+6.59%
1 month-4.37%
3 months+7.15%
6 months+6.98%
Current year-4.57%
1 week 68.02
Extreme 68.02
74.02
1 month 64.57
Extreme 64.5675
79.33
Current year 61.43
Extreme 61.43
90.87
1 year 48.28
Extreme 48.275
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap.
20/8/26
Section Six Partners
SellCompany -12,500 0.0151%
19/8/26 Other

Chairman

0 0%
17/8/26 Fiscal year

General Counsel

8,439 0.0102%
Change 5-day change 1-year change 3-year change Capi.($)
+1.73%-0.19%+47.04%+82.50% 5.93B
+0.63%+2.53%+80.74%+126.99% 1,111B
+0.40%+0.64%+52.93%+64.11% 658B
+0.59%+2.77%+28.21%+81.40% 467B
+0.92%+3.57%+43.82%+44.21% 369B
+1.25%+2.21%+26.77%+43.05% 301B
+3.02%+5.68%+5.09%+17.04% 256B
+0.15%+4.66%+54.30%+73.61% 240B
+2.86%+3.86%-16.20%-51.83% 207B
+0.66%+2.82%+29.21%+91.89% 182B
Average +1.25%+3.79%+35.19%+57.30% 379.69B
Weighted average by Cap. +0.95%+4.67%+47.02%+73.52%

Financials

2026 *2027 *
Net sales 1.26B 1.08B 1.01B 920M 1.74B 120B 1.75B 11.91B 4.63B 60.36B 4.71B 4.61B 200B 1.37B 1.17B 1.1B 1B 1.89B 131B 1.91B 12.99B 5.05B 65.85B 5.14B 5.03B 218B
Net income 144M 124M 116M 106M 200M 13.81B 202M 1.37B 532M 6.94B 542M 530M 22.95B 216M 185M 173M 159M 299M 20.72B 303M 2.05B 798M 10.4B 813M 795M 34.43B
Net Debt -1.87B -1.6B -1.5B -1.37B -2.59B -179B -2.62B -17.75B -6.9B -89.97B -7.03B -6.87B -298B -2.15B -1.84B -1.72B -1.57B -2.97B -205B -3B -20.35B -7.91B -103B -8.06B -7.88B -341B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
26/08/26 USD 72.49 +2.01% 197,501
24/08/26 USD 71.06 +1.78% 897,681
21/08/26 USD 69.82 -0.99% 674,738
20/08/26 USD 70.52 -4.28% 802,507
19/08/26 USD 73.67 +1.43% 1,514,567
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
71.06USD
Average target price
99.29USD
Spread / Average Target
+39.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock